Chapter 36 : Treatment of Parasitic Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Treatment of Parasitic Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819002/9781555819002_ch36-1.gif /docserver/preview/fulltext/10.1128/9781555819002/9781555819002_ch36-2.gif


Chemotherapy plays a very important role not only in reducing patient morbidity and mortality but also in reducing transmission of the parasitic infection. Many of the drugs used to treat parasitic infections have serious side effects; therefore, before initiation of therapy, it is important to consider the following factors: health of the patient, parasite drug resistance, accuracy of the original dose, potential drug toxicity, and the need for follow-up examinations to monitor therapy. The mechanisms of action of most antiparasitic drugs are not well known, including those involving potential drug toxicity to the patient. Because of the limited resources of developing nations, where a majority of parasitic infections occur, there is little commercial incentive for developing effective therapeutics or vaccines. For some drugs, such as triclabendazole, used extensively in veterinary practices, less is known about adverse side effects or toxicity to humans. Specific information can be obtained from the Centers for Disease Control and Prevention, CDC Drug Service, Atlanta, GA (day, 404-639-3670; evenings, weekends, and holidays, 404-639-2888). One can also obtain drugs from CDC that are not commercially available in the United States.

Citation: Garcia L. 2016. Treatment of Parasitic Infections, p 1134-1173. In Diagnostic Medical Parasitology, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819002.ch36
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. The Medical Letter. 2013. Drugs for Parasitic Infections, 3rd ed. The Medical Letter, medicalletter.org.
2. Abramowicz M ( ed). 2004. Drugs for parasitic infections. Med Lett Drugs Ther 46: 112.
3. Anonymous. 2014. Physicians' Desk Reference, 68th ed. Medical Economics, Montvale, NJ.
4. Sweetman S ( ed). 2005. Martindale the Complete Drug Reference. The Pharmaceutical Press, London, United Kingdom.
5. Visvesvara GS. 2013. Infections with free-living amebae. Handb Clin Neurol 114: 153168.
6. Marie C,, Petri WA Jr. 2013. Amoebic dysentery. Clin Evid (Online) Aug 30; 2013. pii: 0918.
7. Fernandez-Diez J,, Magana M,, Magana ML. 2012. Cutis 90: 310314.
8. McCarty TR,, Turkeltaub JA,, Hotez PJ. 2014. Global progress towards eliminating gastrointestinal helminth infections. Curr Opin Gastroenterol 30: 1824.
9. Sawanyawisuth K,, Chotmongkol V. 2013. Eosinophilic meningitis. Handb Clin Neurol 114: 207215.
10. Audicana MT,, Kennedy MW. 2008. Anisakis simplex: from obscure infectious worm to inducer of immune hypersensitivity. Clin Microbiol Rev 21: 360379.
11. Gonzalez P,, Gonzalez FA,, Ueno K. 2012. Ivermectin in human medicine, an overview of the current status of its clinical applications. Curr Pharm Biotechnol 13: 11031109.
12. Hagel I,, Giusti T. 2010. Ascaris lumbricoides: an overview of therapeutic targets. Infect Disord Drug Targets 10: 349367.
13. Vannier E,, Gewurz BE,, Krause PJ. 2008. Human babesiosis. Infect Dis Clin North Am 22: 469488.
14. Kazacos KR,, Jelicks LA,, Tanowitz HB. 2013. Baylisascaris larva migrans. Handb Clin Neurol 114: 251262.
15. Nicoletti A. 2013. Toxocariasis. Handb Clin Neurol 114: 217228.
16. Roberts T,, Stark D,, Harkness J,, Ellis J. 2014. Update on the pathogenic potential and treatment options for Blastocystis sp. Gut Pathog 6: 17.
17. Sekar U,, Shanthi M. 2013. Blastocystis: consensus of treatment and controversies. Trop Parasitol 3: 3539.
18. Addiss DG. 2013. Global elimination of lymphatic filariasis: a “mass uprising of compassion.” PLoS Negl Trop Dis 7: e2264.
19. Xiao SH. 2013. Mefloquine, a new type of compound against schistosomes and other helminthes in experimental studies. Parasitol Res 112: 37233740.
20. Cabada MM,, White AC Jr. 2010. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis 23: 494499.
21. Ortega YR,, Sanchez R. 2010. Update on Cyclospora cayetanensis, a food-borne and waterborne parasite. Clin Microbiol Rev 23: 218234.
22. Macpherson CN. 2013. The epidemiology and public health importance of toxocariasis: a zoonosis of global importance. Int J Parasitol 43: 9991008.
23. Del Brutto OH. 2014. Neurocysticercosis. Handb Clin Neurol 121: 14451459.
24. Chai JY. 2013. Praziquantel treatment in trematode and cestode infections: an update. Infect Chemother 45: 3243.
25. Nagata N,, Marriott D,, Harkness J,, Ellis JT,, Stark D. 2012. Current treatment options for Dientamoeba fragilis infections. Int J Parasitol Drugs Drug Resist 2: 204215.
26. Alvela-Suarez L,, Velanco-Tirado V,, Belhassen-Garcia M,, Novo-Veleiro I,, Pardo-Lledias J,, Romero-Alegria A,, Perez del Villar L,, Valverde-Merino MP,, Cordero-Sanchez M. 2014. Safety of the combined use of praziquantel and albendazole in the treatment of human hydatid disease. Am J Trop Med Hyg 90: 819822.
27. Meilinger M,, Stoeckl C,, Pollheimer M,, Hern P,, Reisinger EC,, Seeber K,, Krause R,, Flick H,, Hoenigl M. 2013. Progressive alveolar echinococcosis after discontinuation of anthelmintic therapy. Parasit Vectors 6: 287.
28. Steinmetz S,, Racloz G,, Stern R,, Dominguez D,, Al-Mayahi M,, Schibler M,, Lew D,, Hoffmeyer P,, Uckay I. 2014. Treatment challenges associated with bone echinococcosis. J Antimicrob Chemother 69: 821826.
29. Watkins RR,, Eckmann L. 2014. Treatment of giardiasis: current status and future directions. Curr Infect Dis Rep 16: 396.
30. Sundar S,, Singh A,, Singh OP. 2014. Strategies to overcome antileishmanial drugs unresponsiveness. J Trop Med 2014: 646932.
31. Hodiamont CJ,, Kager PA,, Bart A,, de Vries HJ,, van Thiel PP,, Leenstra T,, de Vries PJ,, van Vugtt M,, Gobusch MP,, van Gool T. 2014. Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Top Dis 8: e2832.
32. Das S,, Sharma S,, Sahu SK,, Nayak SS,, Kar S. 2012. Diagnosis, clinical features and treatment outcome of microsporidial keratoconjunctivitis. Br J Ophthalmol 96: 793795.
33. Didier ES,, Weiss LM. 2011. Microsporidiosis: not just in AIDS patients. Curr Opin Infect Dis 24: 490495.
34. Marks M,, Gupta-Wright A,, Doherty JF,, Singer M,, Walker D. 2014. Managing malaria in the intensive care unit. Br J Anaesth 113: 910921.
35. Karunamoorthi K. 2014. The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. Malar J 13: 209.
36. Ansari MT,, Saify ZS,, Sultana N,, Ahmad I,, Saeed-Ul-Hassan S,, Tarig I,, Khanum M. 2013. Malaria and artemisinin derivatives: an updated review. Mini Rev Med Chem 13: 18791902.
37. White NJ,, Pukrittayakamee S,, Hien TT,, Faiz MA,, Mokuolu OA,, Dondorp AM. 2014. Malaria. Lancet 383: 723735.
38. Thetiot-Laurent SA,, Boissier J,, Robert A,, Meunier B. 2013. Schistosomiasis chemotherapy. Angew Chem Int Ed Engl. 52: 79367956.
39. Donadello K,, Cristallini S,, Taccone FS,, Lorent S,, Vincent JL,, de Backer D,, Jacobs F. 2013. Strongyloides disseminated infection successfully treated with parenteral ivermectin: case report with drug concentration measurements and review of the literature. Int J Antimicrob Agents 42: 580583.
40. Buonfrate D,, Requena-Mendez A,, Angheben A,, Munoz J,, Gobbi F,, Van Den Ende J,, Bisoffi Z. 2013. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13: 78.
41. Mejia R,, Nutman TB. 2012. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 25: 458463.
42. Montoya JG,, Remington JS. 2008. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 47: 554566.
43. Jones JL,, Parise ME,, Fiore AE. 2014. Neglected parasitic infections in the United States: toxoplasmosis. Am J Trop Med Hyg 90: 794799.
44. Bruschi F,, Brunetti E,, Pozio E. 2013. Neurotrichinellosis. Handb Clin Neurol 114: 243249.
45. Gottstein B,, Pozio E,, Nockler K. 2009. Epidemiology, diagnosis, treatment, and control of trichinellosis. Clin Microbiol Rev 22: 127145.
46. Sena AC,, Bachmann LH,, Hobbs MM. 2014. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther 12: 673685.
47. Goodhew EB,, Secor WE. 2013. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates. Sex Transm Infect 89: 479484.
48. Albajar-Vinas P,, Dias JC. 2014. Advancing the treatment for Chagas' disease. N Engl J Med 370: 19421943.
49. Montgomery SP,, Starr MC,, Cantey PT,, Edwards MS,, Meymandi SK. 2014. Neglected parasitic infections in the United States: Chagas disease. Am J Trop Med Hyg 90: 814818.
50. Babokhov P,, Sanyaolu AO,, Oyibo WA,, Fagbenro-Beyioku AF,, Iriemenam NC. 2013. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health 107: 242252.
51. Lejon V,, Bentivoglio M,, Franco JR. 2013. Human African trypanosomiasis. Handb Clin Neurol 114: 169181.


Generic image for table
TABLE 36.1

Drugs and dosages for treating parasitic infections

Citation: Garcia L. 2016. Treatment of Parasitic Infections, p 1134-1173. In Diagnostic Medical Parasitology, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819002.ch36
Generic image for table
TABLE 36.2

Antiparasitic drugs

Citation: Garcia L. 2016. Treatment of Parasitic Infections, p 1134-1173. In Diagnostic Medical Parasitology, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819002.ch36

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error